Active, not recruitingPhase 1NCT05633459
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
Studying Juvenile amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- QurAlis Corporation
- Principal Investigator
- Angela Genge, MDQurAlis Corporation
- Intervention
- Multiple ascending doses of QRL-201(drug)
- Enrollment
- 69 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2022 – 2026
Study locations (15)
- Universitaire Ziekenhuizen Leuven (UZ Leuven), Leuven, Belgium
- University of Calgary, Calgary, Alberta, Canada
- University of Alberta, Edmonton, Alberta, Canada
- Sunnybrook Health Science Centre, Toronto, Ontario, Canada
- CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
- Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
- Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Bonn, North Rhine-Westphalia, Germany
- Charité Research Organisation, Berlin, Germany
- University Hospital Schleswig-Holstein (UKSH) Campus Lübeck, Department for Neurology/ Precision Neurology, Lübeck, Germany
- Universitätsklinikum Ulm, Ulm, Germany
- St James's Hospital, Dublin, Ireland
- Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
- The University of Sheffield, Royal Hallamshire Hospital, Sheffield, United Kingdom, United Kingdom
- Kings College Hospital NHS Foundation Trust, London, United Kingdom
- National Hospital for Neurology and Neurosurgery, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05633459 on ClinicalTrials.govOther trials for Juvenile amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07118319The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral SclerosisXellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
- RECRUITINGNCT07175935Amyotrophic Lateral Sclerosis Registry in ThailandChulalongkorn University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06392126Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALSn-Lorem Foundation
- RECRUITINGNCT06354244Electroacupuncture of Different Treatment Frequency in Chronic Urinary Retention Caused by Lower Motor Neuron LesionsGuang'anmen Hospital of China Academy of Chinese Medical Sciences
- RECRUITINGNCT05491577Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot FootCentre Hospitalier Universitaire de Nīmes
- RECRUITINGNANCT04868994Magnetic Imaging for Diagnostic of Amyotrophic Lateral SclerosisUniversity Hospital, Toulouse
- ACTIVE NOT RECRUITINGNANCT03766321Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis PatientsAzienda Ospedaliero-Universitaria di Modena
- RECRUITINGNCT02869048Amyotrophic Lateral Sclerosis and the Innate Immune SystemRigshospitalet, Denmark